Detalhe da pesquisa
1.
Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response.
Hepatology
; 60(4): 1187-95, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25065814
2.
Telaprevir-induced DRESS.
J Drugs Dermatol
; 13(2): 199-200, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24509972
3.
Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection.
World J Hepatol
; 9(11): 551-561, 2017 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-28469811
4.
Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus.
World J Gastroenterol
; 22(9): 2844-54, 2016 Mar 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-26973423
5.
Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus.
World J Gastroenterol
; 21(20): 6236-45, 2015 May 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-26034358
6.
Serum and ascites chromogranin-A in patients with metastatic neuroendocrine tumors.
Pancreas
; 40(4): 622-6, 2011 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-21483253
7.
Cross-genotypic polyclonal anti-HCV antibodies from human ascitic fluid.
J Virol Methods
; 171(1): 169-75, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21034775
8.
An escalating dose regimen of pegylated interferon and ribavirin in HCV cirrhotic patients referred for liver transplant.
Transplantation
; 88(5): 729-35, 2009 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19741473